Related Experiment Video
Updated: Apr 17, 2026
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
14.0K
Systemic Treatments of Castration-Resistant Prostate Cancer
Akshay N Desai1, Michelle Fleyshman2, Naveena Lall1
1Department of Hematology/Oncology, Maimonides Health, Maimonides Medical Center, Brooklyn, NY, USA.
The Urologic Clinics of North America
|April 15, 2026
Summary
Metastatic castrate-resistant prostate cancer arises from hormone therapy resistance in metastatic patients or progression after non-metastatic treatments. Understanding these pathways is crucial for improving prostate cancer outcomes.
Area of Science:
- Oncology
- Urology
Background:
- Prostate cancer can become resistant to hormone therapies.
- Metastatic castrate-resistant prostate cancer (mCRPC) presents a significant clinical challenge.
Purpose of the Study:
- To elucidate the distinct pathways leading to the development of mCRPC.
- To inform therapeutic strategies for advanced prostate cancer.
Main Methods:
- Review of clinical progression patterns in prostate cancer patients.
- Analysis of treatment resistance mechanisms in hormone-naive and hormone-treated cohorts.
Main Results:
- mCRPC develops through two primary routes: initial resistance in metastatic disease or progression after curative/hormonal therapies in non-metastatic settings.
- These distinct origins may influence treatment response and prognosis.
Conclusions:
- Identifying the specific pathway to mCRPC is essential for personalized treatment planning.
- Further research into resistance mechanisms can guide the development of novel therapies for prostate cancer.
Related Concept Videos
02:56Treatment Resistent Cancers
1.5K
1.5K
02:56Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
02:57Targeted Cancer Therapies
9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.2K
01:20Disorders of the Male Reproductive System
5.6K
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
5.6K
02:49Cancer Therapies
10.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.8K
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
667
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
667